An Extension to Study MD7108240

Summary

An Extension to Study MD7108240 is a clinical trial^[1].

Key Facts

• An Extension to Study MD7108240 is in the country of Australia^[2].
• An Extension to Study MD7108240 is in the country of Italy^[3].
• An Extension to Study MD7108240 is in the country of United States^[4].
• An Extension to Study MD7108240's instance of is recorded as clinical trial^[5].
• An Extension to Study MD7108240's start time is recorded as +2008-06-25T00:00:00Z^[6].
• An Extension to Study MD7108240's end time is recorded as +2009-09-09T00:00:00Z^[7].
• An Extension to Study MD7108240's sponsor is recorded as GSK^[8].
• An Extension to Study MD7108240's main subject is recorded as Vascular endothelial growth factor (VEGF) IRES A^[9].
• An Extension to Study MD7108240's main subject is recorded as macular degeneration^[10].
• An Extension to Study MD7108240's number of participants is recorded as {'unit': '1', 'amount': '+42'}^[11].
• An Extension to Study MD7108240's title is recorded as An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration^[12].
• An Extension to Study MD7108240's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+50'}^[13].
• An Extension to Study MD7108240's ClinicalTrials.gov ID is recorded as NCT00733304^[14].
• An Extension to Study MD7108240's research intervention is recorded as eye drop^[15].
• An Extension to Study MD7108240's clinical trial phase is recorded as phase II clinical trial^[16].
• An Extension to Study MD7108240's research site is recorded as GSK^[17].
• An Extension to Study MD7108240's research subject recruitment status is recorded as completed^[18].
• An Extension to Study MD7108240's study type is recorded as interventional study^[19].